| Name | Title | Contact Details |
|---|
Blue Giant Equipment Corporation is a prominent global manufacturer and distributor of loading dock systems and material handling equipment, headquartered in Toronto, Ontario, Canada. Founded in 1963 by Kurt Larsen, the company has celebrated over 60 years of innovation in the industry. Blue Giant began with mechanical dock levelers and hand pallet trucks, later expanding its offerings to include intelligent dock controls and air-powered loading dock equipment. The company provides a wide range of products, including loading dock systems, material handling equipment, HVLS fans, and ergonomic lift assist solutions. Their innovative Blue Genius Connect control panel enhances the management of loading dock operations. Blue Giant has received multiple awards for its products, including recognition in the Professional Door Dealer magazines "Best of Business Dealers Choice Poll" and a Bronze Award from Plant Engineering magazine. With a commitment to growth, Blue Giant relocated its headquarters in 2017 to a larger facility in Mississauga, Ontario, reflecting its dedication to expanding its capabilities in the material handling sector.
AprotekUSA turns YOUR liquid waste stream into a solid in real-time. SAVE MONEY💲 BY SOLIDIFYING YOUR SLUDGE 🌎We specialize in the recycling and manufacture of super-absorbent products. Since 2013, weve been working with public and private companies to solve their problems relating to sludge containment, water absorption and retention, impermeability and liquid solidification. Our core business? MUDS and LIQUID DEBLAYS. 💩 Our range of APROMUD® super-settlers is formidable when it comes to solidifying sludge, whatever its origin or composition. Sludge from construction sites, WWTPs, HDD, tunneling, mines & quarries, pond cleaning, concrete plants, drilling we have developed low-carbon solutions to make it easier for you to handle, transport and recycle your sludge while saving you . 🌱
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.